Lupus Erythematosus, Systemic
169
21
35
80
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
34 trials with published results (20%)
Research Maturity
80 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.2%
19 terminated out of 169 trials
80.8%
-5.7% vs benchmark
17%
29 trials in Phase 3/4
43%
34 of 80 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 80 completed trials
Clinical Trials (169)
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Engagement in CHildhood-Onset Systemic Lupus
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Omega-3 Supplementation in Systemic Lupus Erythematosus
Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
Trial of Belimumab in Early Lupus